Möchten Sie immer auf dem neuesten Stand bleiben?

AUSTIN, Texas, May 13, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (T2DM) rank among the most urgent and costly healthcare problems facing the world...

The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion...

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of careFirst 45-subject data unblinding expected before June 30,...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress Scripts national formulary coverage secured as company...

MITOLINE®-Powered Platform Delivers Optimized Hit Molecule, Strengthening the Foundation for Future Pre-Clinical and Commercial Development Neve Yarak, Israel, May 13, 2026 (GLOBE NEWSWIRE) --...

Planet Fitness Inquiry Alert: Investors with Losses after Cancellation Rates are Urged to Contact BFA Law about its Securities Investigation

Dublin, May 13, 2026 (GLOBE NEWSWIRE) -- The "Digital Biomarkers Market by Type, Therapy, Application, End User - Global Forecast to 2031" has been added to ResearchAndMarkets.com's offering.The...

C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of...

Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment

400mg QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting advancement in registration-intended trialsDENALI Phase 2...